1. Remyelination in humans due to a retinoid-X receptor agonist is age-dependent.
- Author
-
McMurran CE, Mukherjee T, Brown JWL, Michell AW, Chard DT, Franklin RJM, Coles AJ, and Cunniffe NG
- Subjects
- Age Factors, Aged, Animals, Evoked Potentials, Visual drug effects, Evoked Potentials, Visual physiology, Humans, Multiple Sclerosis complications, Multiple Sclerosis drug therapy, Multiple Sclerosis physiopathology, Retinoids administration & dosage, Retinoids pharmacology, Bexarotene pharmacology, Bexarotene therapeutic use, Optic Nerve Diseases drug therapy, Optic Nerve Diseases etiology, Optic Nerve Diseases physiopathology, Peripheral Nervous System Agents pharmacology, Peripheral Nervous System Agents therapeutic use, Remyelination drug effects, Remyelination physiology, Retinoid X Receptors administration & dosage, Retinoid X Receptors agonists, Retinoid X Receptors pharmacology
- Abstract
Remyelination efficiency declines with advancing age in animal models, but this has been harder to demonstrate in people with multiple sclerosis. We show that bexarotene, a putatively remyelinating retinoid-X receptor agonist, shortened the visual evoked potential latency in patients with chronic optic neuropathy aged under 42 years only (with the effect diminishing by 0.45 ms per year of age); and increased the magnetization transfer ratio of deep gray matter lesions in those under 43 years only. Addressing this age-related decline in human remyelination capacity will be an important step in the development of remyelinating therapies that work across the lifespan., (© 2022 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.)
- Published
- 2022
- Full Text
- View/download PDF